ClinicalTrials.gg
CompletedNCT03697252EMERGENT-1Updated Oct 26, 2020Results posted

A Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia

A Phase 2 interventional study of Xanomeline and Trospium Chloride Capsules and Placebo Capsules in Schizophrenia, sponsored by Karuna Therapeutics. Completed at 12 sites in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2020-10-26.

Sponsored by Karuna Therapeutics (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
182
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing xanomeline in Schizophrenia — 9 open to participants now, 9 under way, 4 of them phase 3. xanomeline · Schizophrenia.

Enrollment
10th of 20
182 · median 178
Started
2018
the only one that year
Phase 2
Only one
of the 20
Registered
1st of 20
by date
Lead sponsor
5 of 20
Karuna Therapeutics

Among the 20 studies testing xanomeline in Schizophrenia, this one is the 10th largest by enrollment, is the only one that started in 2018, is the only one in phase 2, and was the 1st registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

9 of the 20 studies testing xanomeline in Schizophrenia are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About xanomeline

xanomeline: first FDA approval 2024 (COBENFY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing xanomeline in Schizophrenia, or all of them as a file.
02

Study summary

This is a Phase 2, randomized, double-blinded, placebo-controlled, inpatient study to examine the efficacy, safety, and tolerability profile of KarXT in adult subjects diagnosed with DSM-5 schizophrenia who are in an acute exacerbation phase. The primary objective of the study is to assess the efficacy of KarXT (a fixed combination of xanomeline and trospium chloride) (xanomeline 125 mg/trospium 30 mg twice daily [BID]) versus placebo in reducing Positive and Negative Syndrome Scale (PANSS) total scores in adult inpatients with a Diagnostic and Statistical Manual-Fifth Edition (DSM-5) diagnosis of schizophrenia. The secondary objectives of the study are to assess overall safety and tolerability of KarXT in adult inpatients with a DSM-5 diagnosis of schizophrenia.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is aged 18-60 years, inclusive, at screening
  2. Subject has a primary diagnosis of schizophrenia established by a comprehensive psychiatric evaluation based on the (American Psychiatric Association 2013) criteria and confirmed by Mini International Neuropsychiatric Interview for Schizophrenia and Psychotic Disorder Studies (MINI) version 7.0.2.
  3. Subject is experiencing an acute exacerbation or relapse of symptoms, with onset less than 2 months before screening
  4. Positive and Negative Syndrome Scale total score between 80 and 120, inclusive, at screening

    1. Score of ≥ 4 (moderate or greater) for ≥ 2 of the following Positive Scale (P) items at screening:
    2. Item 1 (P1; delusions)
    3. Item 2 (P2; conceptual disorganization)
    4. Item 3 (P3; hallucinatory behavior)
    5. Item 6 (P6; suspiciousness/persecution)
  5. There should not be a change (improvement) in PANSS total score between screening and baseline of more than 20%
  6. Subjects taking a depot antipsychotic could not have received a dose of medication for at least 1 and a half injection cycles before baseline (eg, 3 or more weeks off for a 2-week cycle)
  7. Subject is capable of providing

    1. A signed ICF must be provided before any study assessments are performed
    2. Subject must be fluent (oral and written) in English in order to consent
  8. Subject must have CGI-S score of ≥ 4 at screening and baseline visits
  9. must be ≥ 18 and ≤ 40 kg/m2
  10. Both females of child bearing potential and males with partners of child bearing potential must be willing to use a double-barrier method of (ie, any double combination of male or female condom with spermicidal gel, diaphragm, sponge, or cervical cap with spermicidal gel) during the study and for 7 days after the last dose of study drug.
  11. Subject has an identified reliable informant

Exclusion criteria

Exclusion Criteria:

  1. Any primary disorder other than schizophrenia within 12 months before screening (confirmed using MINI version 7.0.2 at screening)
  2. History or presence of cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or oncologic disease or any other condition that, in the opinion of the investigator, would jeopardize the safety of the subject or the validity of the study results, to exclude patients with (HIV), cirrhosis, biliary duct abnormalities, hepatobiliary carcinoma, and/or active hepatic viral infections based on the liver function test results.
  3. History of or high risk of urinary retention, gastric retention, or narrow-angle glaucoma
  4. History of irritable bowel syndrome (with or without constipation) or serious constipation requiring treatment within the last 6 months
  5. Has a DSM-5 diagnosis of moderate to severe substance abuse disorder (except tobacco use disorder) within the 12 months before screening (confirmed using MINI version 7.0.2 at screening), or current abuse as determined by urine toxicology screen or alcohol test. A screening subject with mild substance abuse disorder within the 12 months before screening must be discussed and agreed upon with the medical monitor before he/she can be allowed into the study.
  6. Clinically significant abnormal finding on the physical examination, medical history, , or clinical laboratory results at screening
  7. Pregnant, lactating, or less than 3 months postpartum. Sperm donation is not allowed for 90 days after the final dose of study drug
  8. If, in the opinion of the investigator (and/or Sponsor), subject is unsuitable for enrollment in the study or subject has any finding that, in the view of the investigator (and/or Sponsor), may compromise the safety of the subject or affect their ability to adhere to the protocol visit schedule or fulfill visit requirements
  9. Subject has had psychiatric hospitalization(s) for more than 30 days (cumulative) during the 90 days before screening
  10. Subject has a history of treatment resistance to schizophrenia medications defined as failure to respond to 2 adequate courses of pharmacotherapy (a minimum of 4 weeks at an adequate dose per the label) or required clozapine within the last 12 months
  11. Risk of violent or destructive behavior
  12. Current involuntary hospitalization or incarceration
  13. Participation in another clinical study in which the subject received an experimental or drug agent within 3 months of screening
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
182 participants (actual)

Study arms

  • Experimental
    KarXT

    Drug: Xanomeline and Trospium Chloride Capsules

  • Placebo comparator
    Placebo

    Drug: Placebo Capsules

Interventions

  • DrugXanomeline and Trospium Chloride Capsules

    Drug pages: Xanomeline · Trospium chloride

    Xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-34 unless the subject is experiencing adverse events from the xanomeline 100 mg/trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/trospium 20 mg depending on clinical response and tolerability. Dosing must not change after Visit 7 of the study (at 21 ± 2 days of dosing) and may be decreased for tolerability reasons no more than once during the study.

    Also known as: KarXT

  • DrugPlacebo Capsules

    Placebo Capsules

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5

    The PANSS is a medical scale used for measuring symptom severity of participants with schizophrenia. The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants were rated from 1 to 7 on each symptom scale. The total score is the sum of all scales with a minimum score of 30 and a maximum score of 210. A decrease in PANSS total score correlates with an improvement in schizophrenia symptoms.

    Time frame: Baseline and Week 5

Secondary outcomes

  1. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Positive Score at Week 5

    The PANSS is a medical scale used for measuring symptom severity of participants with schizophrenia. The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. The positive symptoms in schizophrenia are the excess or distortion of normal functions such as hallucinations, delusions, grandiosity, and hostility. Participants were rated from 1 to 7 on each symptom scale, with a minimum score of 7 and a maximum score of 49. A decrease in PANSS total score correlates with an improvement in schizophrenia symptoms.

    Time frame: Baseline and Week 5

  2. Number of Participants With Each Clinical Global Impression - Severity (CGI-S) Score at Baseline and 5 Weeks

    The CGI-S modified asked the clinician 1 question: "Considering your total clinical experience, how mentally ill is the participant at this time?" The clinician's answer rated on the following 7-point scale: 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participants.

    Time frame: Baseline and Week 5

  3. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Negative Score at Week 5

    The PANSS is a medical scale used for measuring symptom severity of participants with schizophrenia. The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. The negative symptoms in schizophrenia are the diminution or loss of normal functions. Participants were rated from 1 to 7 on each symptom scale, with a minimum score of 7 and a maximum score of 49. A decrease in PANSS total score correlates with an improvement in schizophrenia symptoms.

    Time frame: Baseline and Week 5

  4. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Marder Factor Score

    The Marder Negative Factor score is derived from the PANSS and consists of the sum of 5 negative scales (N) and 2 general scales (G) (N1. Blunted affect; N2. Emotional withdrawal; N3. Poor rapport; N4. Passive/apathetic social withdrawal; N6. Lack of spontaneity; G7. Motor retardation; and G16. Active social avoidance), with a minimum score of 7 and a maximum score of 49.

    Time frame: Baseline and Week 5

  5. Percentage of Participants Who Were Clinical Global Impression - Severity of Illness (CGI-S) Responders

    The CGI-S modified asks the clinician 1 question: "Considering your total clinical experience, how mentally ill is the participant at this time?" The clinician's answer was rated on the following 7-point scale: 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participants. A CGI-S responder is defined as a participant with a CGI-S scale equal to 1 or 2.

    Time frame: Week 5

07

Results

Posted Sep 28, 2020

Participant flow

The study was conducted in 12 study centers in North America.

Participant flow — Overall Study
MilestoneKarXTPlacebo
Started9092
Completed7273
Not completed1819
Withdrew: Adverse event32
Withdrew: Withdrawal by subject1414
Withdrew: Lost to follow-up01
Withdrew: Physician decision11
Withdrew: Other01

Outcome measures

PrimaryChange From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5

The PANSS is a medical scale used for measuring symptom severity of participants with schizophrenia. The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants were rated from 1 to 7 on each symptom scale. The total score is the sum of all scales with a minimum score of 30 and a maximum score of 210. A decrease in PANSS total score correlates with an improvement in schizophrenia symptoms.

Time frame:
Baseline and Week 5
Reported as:
Least squares mean · score on a scale
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5
score on a scaleKarXTPlacebo
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5-17.40 ± 1.749-5.85 ± 1.668
Statistical analysis
  • KarXT vs Placebo · Mixed model for repeated measures · p = <0.0001 · Ls mean difference: -11.56 · 95% CI -16.07 to -7.05
SecondaryChange From Baseline in Positive and Negative Syndrome Scale (PANSS) Positive Score at Week 5

The PANSS is a medical scale used for measuring symptom severity of participants with schizophrenia. The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. The positive symptoms in schizophrenia are the excess or distortion of normal functions such as hallucinations, delusions, grandiosity, and hostility. Participants were rated from 1 to 7 on each symptom scale, with a minimum score of 7 and a maximum score of 49. A decrease in PANSS total score correlates with an improvement in schizophrenia symptoms.

Time frame:
Baseline and Week 5
Reported as:
Least squares mean · score on a scale
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Positive Score at Week 5
score on a scaleKarXTPlacebo
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Positive Score at Week 5-5.62 ± 0.601-2.38 ± 0.573
SecondaryNumber of Participants With Each Clinical Global Impression - Severity (CGI-S) Score at Baseline and 5 Weeks

The CGI-S modified asked the clinician 1 question: "Considering your total clinical experience, how mentally ill is the participant at this time?" The clinician's answer rated on the following 7-point scale: 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participants.

Time frame:
Baseline and Week 5
Reported as:
Count of participants · Participants
Number of Participants With Each Clinical Global Impression - Severity (CGI-S) Score at Baseline and 5 Weeks
ParticipantsKarXTPlacebo
Baseline: Score = 100
Week 5: Score = 110
Baseline: Score = 200
Week 5: Score = 231
Baseline: Score = 300
Week 5: Score = 3237
Baseline: Score = 41317
Week 5: Score = 42121
Baseline: Score = 56060
Week 5: Score = 52138
Baseline: Score = 6109
Week 5: Score = 624
Baseline: Score = 701
Week 5: Score = 712
Statistical analysis
  • KarXT vs Placebo · Wilcoxon (Mann-Whitney) · p = <0.001
SecondaryChange From Baseline in Positive and Negative Syndrome Scale (PANSS) Negative Score at Week 5

The PANSS is a medical scale used for measuring symptom severity of participants with schizophrenia. The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. The negative symptoms in schizophrenia are the diminution or loss of normal functions. Participants were rated from 1 to 7 on each symptom scale, with a minimum score of 7 and a maximum score of 49. A decrease in PANSS total score correlates with an improvement in schizophrenia symptoms.

Time frame:
Baseline and Week 5
Reported as:
Least squares mean · score on a scale
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Negative Score at Week 5
score on a scaleKarXTPlacebo
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Negative Score at Week 5-3.18 ± 0.481-0.90 ± 0.454
SecondaryChange From Baseline in Positive and Negative Syndrome Scale (PANSS) Marder Factor Score

The Marder Negative Factor score is derived from the PANSS and consists of the sum of 5 negative scales (N) and 2 general scales (G) (N1. Blunted affect; N2. Emotional withdrawal; N3. Poor rapport; N4. Passive/apathetic social withdrawal; N6. Lack of spontaneity; G7. Motor retardation; and G16. Active social avoidance), with a minimum score of 7 and a maximum score of 49.

Time frame:
Baseline and Week 5
Reported as:
Least squares mean · score on a scale
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Marder Factor Score
score on a scaleKarXTPlacebo
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Marder Factor Score-3.85 ± 0.520-1.32 ± 0.492
SecondaryPercentage of Participants Who Were Clinical Global Impression - Severity of Illness (CGI-S) Responders

The CGI-S modified asks the clinician 1 question: "Considering your total clinical experience, how mentally ill is the participant at this time?" The clinician's answer was rated on the following 7-point scale: 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participants. A CGI-S responder is defined as a participant with a CGI-S scale equal to 1 or 2.

Time frame:
Week 5
Reported as:
Number · percentage of participants
Percentage of Participants Who Were Clinical Global Impression - Severity of Illness (CGI-S) Responders
percentage of participantsKarXTPlacebo
Percentage of Participants Who Were Clinical Global Impression - Severity of Illness (CGI-S) Responders5.61.4

Adverse events

Collected over From the start of study drug administration up to Week 5. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
KarXT0/89 (0%)1/89 (1.1%)48/89 (53.9%)
Placebo0/90 (0%)0/90 (0%)39/90 (43.3%)
Most frequent serious events
Most frequent serious events
EventKarXTPlacebo
Psychotic disorderPsychiatric disorders1/890/90
Most frequent other events
Showing 10 of 18
Most frequent other events
EventKarXTPlacebo
ConstipationGastrointestinal disorders15/893/90
NauseaGastrointestinal disorders15/894/90
Dry mouthGastrointestinal disorders8/891/90
DyspepsiaGastrointestinal disorders8/894/90
VomitingGastrointestinal disorders8/894/90
HeadacheNervous system disorders6/895/90
SomnolenceNervous system disorders5/894/90
Weight increasedInvestigations3/894/90
DiarrhoeaGastrointestinal disorders2/894/90
AkathisiaNervous system disorders3/890/90

Baseline characteristics

The Intent-to-Treat (ITT) population included all participants who were randomized to the study. Participants were analyzed according to randomized treatment.

Age, Continuous
Age, Continuous(years)KarXTPlaceboTotal
Mean43.4 ± 10.1241.6 ± 10.0842.5 ± 10.11
Sex: Female, Male
Sex: Female, Male(Participants)KarXTPlaceboTotal
Female182442
Male7268140
Race (NIH/OMB)
Race (NIH/OMB)(Participants)KarXTPlaceboTotal
American Indian or Alaska Native000
Asian224
Native Hawaiian or Other Pacific Islander112
Black or African American6770137
White201737
More than one race000
Unknown or Not Reported022
08

Study locations

12 sites
  • Woodland International Research Group, LLC
    Little Rock, Arkansas 72211, United States
  • Synergy East
    Lemon Grove, California 91945, United States
  • Collaborative Neuroscience Network, LLC.
    Long Beach, California 90806, United States
  • NRC Research Institute
    Orange, California 92868, United States
  • Artemis Institute for Clinical Research
    San Diego, California 92103, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • CBH Health, LLC
    Gaithersburg, Maryland 20877, United States
  • Hassman Research Institute
    Berlin, New Jersey 08009, United States
  • Midwest Clinical Research Center (and IP Shipment)
    Dayton, Ohio 45417, United States
  • Community Clinical Research, Inc.
    Austin, Texas 78754, United States
  • InSite Clinical Research, LLC
    DeSoto, Texas 75115, United States
  • Pillar Clinical Research, LLC
    Richardson, Texas 75080, United States
09

References and documents

Publications

  • Weiden PJ, Breier A, Kavanagh S, Miller AC, Brannan SK, Paul SM. Antipsychotic Efficacy of KarXT (Xanomeline-Trospium): Post Hoc Analysis of Positive and Negative Syndrome Scale Categorical Response Rates, Time Course of Response, and Symptom Domains of Response in a Phase 2 Study. J Clin Psychiatry. 2022 May 11;83(3):21m14316. doi: 10.4088/JCP.21m14316. PubMed 35552528 ↗
  • Targum SD, Murphy C, Breier A, Brannan SK. Site-independent confirmation of primary site-based PANSS ratings in a schizophrenia trial. J Psychiatr Res. 2021 Dec;144:241-246. doi: 10.1016/j.jpsychires.2021.10.027. Epub 2021 Oct 21. PubMed 34700212 ↗
  • Brannan SK, Sawchak S, Miller AC, Lieberman JA, Paul SM, Breier A. Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia. N Engl J Med. 2021 Feb 25;384(8):717-726. doi: 10.1056/NEJMoa2017015. PubMed 33626254 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2018 to primary completion in Sep 2019, 11 months.

Results were first posted in Sep 2020, 1 year after primary completion.

Of 57 industry-sponsored phase 2 interventional studies under Schizophrenia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 32. This study's 11 months is below that.

Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2018
First posted
Oct 5, 2018
StartActual
Sep 18, 2018
Primary completionActual
Sep 4, 2019
CompletionActual
Sep 4, 2019
Results first posted
Sep 28, 2020
Last update
Oct 26, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03697252
Responsible party
Sponsor
First posted
Oct 5, 2018
Start date
Sep 18, 2018
Primary completion
Sep 4, 2019
Completion
Sep 4, 2019
Results posted
Sep 28, 2020
Last update
Oct 26, 2020

Study contacts

Stephen Brannan, MD
study director · Karuna Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Xanomeline · Trospium chloride

Start the discussion